Collegium Pharmaceutical Inc represents a set of values and a corporate philosophy that guide its operations. The company is committed to improving patients' lives by developing and delivering innovative and abuse-deterrent therapies. Collegium places great importance on innovation, patient focus, and responsibility to shareholders. With a strong dedication to research and development, Collegium aims to address unmet medical needs and enhance patient outcomes. By continuously striving for excellence, Collegium Pharmaceutical Inc aims to maintain its position as a leading provider of pharmaceutical solutions.

Collegium Pharmaceutical Inc is primarily present in the United States.

Collegium Pharmaceutical Inc has achieved several significant milestones. One notable achievement of the company was the FDA approval of its product Xtampza ER, an abuse-deterrent opioid medication for the management of severe pain. This approval showcases Collegium Pharmaceutical's dedication to developing innovative treatment options. Additionally, the company successfully launched Xtampza ER and established partnerships with reputable pharmaceutical companies for commercialization. Collegium Pharmaceutical Inc has also demonstrated continuous growth and expansion, reflecting its commitment to providing effective and safe medications to patients. Through its notable achievements, Collegium Pharmaceutical Inc has solidified its position as a leading player in the pharmaceutical industry.

Collegium Pharmaceutical Inc is a pharmaceutical company specializing in the development and commercialization of innovative prescription products for pain management. Founded in 2002, Collegium Pharmaceuticals has a strong history of delivering effective treatments for pain while striving to address the challenges associated with opioid misuse and abuse. The company focuses on utilizing its proprietary DETERx platform to develop abuse-deterrent medications for the treatment of various pain conditions. Collegium Pharmaceutical Inc aims to provide healthcare professionals and patients with safe and effective options for pain management, contributing to improved patient outcomes and reducing the risk of opioid abuse.

The main competitors of Collegium Pharmaceutical Inc in the market are pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., and AstraZeneca.

Collegium Pharmaceutical Inc is primarily active in the pharmaceutical industry.

Collegium Pharmaceutical Inc operates under a business model focused on developing and commercializing innovative medicines. As a specialty pharmaceutical company, Collegium specializes in developing products for the treatment of pain and related conditions. The company's primary goal is to provide patients with effective, safe, and abuse-deterrent pain management solutions. Collegium Pharmaceutical Inc strives to continually advance its portfolio by leveraging its proprietary technology platform, known as DETERx®, to enhance the delivery of active ingredients. This innovative business model allows Collegium to bring valuable medications to market while prioritizing patient safety and therapeutic effectiveness.

Collegium Pharmaceutical hissesinin F/K oranı 7,82.

Collegium Pharmaceutical KUV 2,56 dir.

Collegium Pharmaceutical için AlleAktien Kalite Skoru 6/10'dur.

beklenen Collegium Pharmaceutical cirosu 631,87 Milyon. USD dir.

beklenen Collegium Pharmaceutical karı 206,60 Milyon. USD olarak gerçekleşmiştir.

Collegium Pharmaceutical Inc is an innovative company specialized in the development and marketing of medications for patients with pain and inflammation conditions. The company's business model is based on innovation and providing a differentiated product range to meet the needs of their target audience. The company offers a wide range of products, including opioid analgesics and narcotic antagonists. Collegium offers various branded medications such as Xtampza® ER, Nucynta® ER, and DETERx®, all of which have different effects on the body and are suitable for different pain conditions. The company's main focus is on research and development of new medications. Collegium dedicates significant financial resources to the research and development of pain treatment drugs. They have a variety of patented drugs in the development phase and are continuously striving to improve therapy options for pain patients. Additionally, Collegium invests in expanding its business model into new markets. The company has expanded its presence in international markets to reach a larger customer base and expand their business. Through partnerships with local companies, Collegium has increased its reach and global presence. Collegium also constantly strives to improve the efficiency and effectiveness of its business processes. The company invests in technology and automation to improve operational efficiency and enhance product quality. This also helps to identify cost savings in areas such as sales, procurement, and inventory management. Another important aspect of Collegium's business model is its partnership with service providers and distributors. The company works closely with pharmacies, medical facilities, and other healthcare organizations to sell its products and services. These partnerships bring additional sales and increase Collegium's visibility and credibility in the industry. Overall, Collegium offers a broad and esteemed portfolio of pain medications. The company follows an innovative business model based on strong innovation, partnerships, expansion into new markets, and a focus on efficient business processes. Collegium will continue to actively strive to maintain its position as a leading company in pain treatment and expand its business on a continuous basis.

Collegium Pharmaceutical, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Collegium Pharmaceutical için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Collegium Pharmaceutical şirketinin ISIN kodu US19459J1043’dir.

Collegium Pharmaceutical 'nin WKN'si A14SUV 'dir.

Collegium Pharmaceutical için Ticker COLL’dir.

Son 12 ay içerisinde Collegium Pharmaceutical, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Collegium Pharmaceutical, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Collegium Pharmaceutical şirketinin mevcut temettü verimi .

Collegium Pharmaceutical dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Collegium Pharmaceutical, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Collegium Pharmaceutical, 'Sağlık' sektörüne atanmıştır.

Son Collegium Pharmaceutical tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 01.10.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 01.10.2024 olarak gerçekleşti.

2023 yılında Collegium Pharmaceutical tarafından 0 USD olarak temettüler dağıtıldı.

Collegium Pharmaceutical hisselerinin temettüleri USD olarak dağıtılır.